

*Application  
for  
United States Letters Patent*

**To all whom it may concern:**

Be it known that, we,  
Adrian Gilbert, Rivka Riven-Kreitman, Milka Lenenberg,  
Sharon Cohen-Vered and Ramon F. Joubran

have invented certain new and useful improvements in  
ORAL, NASAL AND PULMONARY DOSAGE FORMULATIONS OF COPOLYMER 1

of which the following is a full, clear and exact description.

**ORAL, NASAL AND PULMONARY DOSAGE FORMULATIONS OF COPOLYMER 1**


5 This application is a continuation-in-part of and claims the benefit of U.S. Provisional Application No. 60/183,666, filed February 18, 2000, the contents of which are hereby incorporated by reference.

10 Throughout this application, various references are cited. These publications, in their entireties, are hereby incorporated by reference to more fully describe the state of the art to which the invention pertains.

15 **Introduction**

The present invention provides oral, nasal and pulmonary dosage formulations of Copolymer 1. COPAXONE® is the brand name for glatiramer acetate (also known as Copolymer 1). Glatiramer acetate (GA), the active ingredient of COPAXONE®, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with average molar fractions of [L-Glu: 0.129-0.153; L-Ala: 0.392-0.462; L-Tyr: 0.086-0.100; L-Lys: 0.300-0.374] respectively. The average molecular weight of glatiramer acetate is 4,700 - 11,000 daltons. Chemically, glatiramer acetate is designated L-glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt). Its structural formula is:

30



35 ("Copaxone", Physician's Desk Reference, (2000), Medical Economics Co., Inc., (Montvale, NJ), 3115.) Glatiramer acetate

is also written as: poly [L-Glu<sup>13-15</sup>, L-Ala<sup>39-46</sup>, L-Tyr<sup>8.6-10</sup>, L-Lys<sup>30-37</sup>].n CH<sub>3</sub>COOH. Copolymer 1 is widely believed to be effective in treating a variety of immune system conditions. A common method of administering the drug is subcutaneous injection. However, such administration often results in injection site reactions such as irritation, hypersensitivity, inflammation and pain. In addition, it tends to be difficult to persuade patients to adhere to the prescribed dosing regimes. To overcome these difficulties, oral, nasal and pulmonary dosage formulations are desirable. This invention provides compositions of and processes for creating solid, semisolid and aqueous dosage forms intended for oral, nasal and pulmonary administration.

#### **Background of the Invention**

Autoimmune diseases occur when a mammal's immune system fails to recognize some of the mammal's own tissues as "self" and attacks them as "foreign". Normally, self-tolerance is developed early by developmental events within the immune system that prevent the mammal's T cell and B cells from reacting with the mammal's own tissues. Major Histocompatibility Complex (Major Histocompatibility Complex) cell surface proteins help regulate these early immune responses by binding to and presenting processed peptides to T cells.

When this self-tolerance breaks down, autoimmune diseases develop. Now, the mammal's own tissues and proteins are recognized as "antigens" and are attacked by the mammal's immune system. For example, multiple sclerosis is believed to be an autoimmune disease that occurs when the immune system attacks the myelin sheath. This sheath is thought to insulate and protect the nerves. The disease is a progressive one, characterized by demyelination, followed by neuronal loss and motor function loss. An additional example is rheumatoid arthritis ("RA"). RA is believed to be an autoimmune disease

arthritis ("RA"). RA is believed to be an autoimmune disease which involves chronic inflammation of the synovial joints and infiltration by activated T cells, macrophages and plasma cells. This inflammation is thought to lead to a progressive destruction of the articular cartilage. It is the most severe form of joint disease. The nature of the autoantigen(s) attacked in rheumatoid arthritis is poorly understood, but collagen type II is a candidate.

Like autoimmune diseases, rejection of transplanted tissue also involves a hyper-response by the immune system to an antigen. This is manifested as graft rejection in the case of organ transplantation (host-versus-graft disease, or HVGD). Another manifestation of pathological immune reactivity is graft-versus-host disease (GVHD) that occurs in approximately 30% of bone marrow recipients. Up to half of those patients who develop GVHD may succumb to this process. This high morbidity and mortality has led to continuous interest in the possibility of controlling or preventing GVHD.

There are two forms of GVHD, acute and chronic. Acute GVHD develops within the first 3 months after bone marrow transplantation and features disorders of skin, liver and gastrointestinal tract. Chronic GVHD is a multiorgan autoimmune-like disease, emerging from 3 months up to 3 years post-transplantation and shares features common to naturally occurring autoimmune disorders, like systemic lupus erythematosus (SLE) and scleroderma.

Studies on the effect of Copolymer 1 on various processes involved in the pathological course of immune rejection showed that Copolymer 1 inhibited T cell proliferation in response to host cell (Aharoni et al., Immunology Letters 58(2):79-87, 1997). Copolymer 1 treatment completely abolished cytotoxic activity toward grafts, prevented the pro-GVHD IL-2 and IFN- $\gamma$

cytokine secretion, and induced beneficial Th2 anti-inflammatory response. In view of these cumulative data, Copolymer 1 is a candidate drug for the prevention of HVGD and GVHD in humans. See WO 96/32119 and U.S. Patent No. 5,858,964.

5 Copolymer 1 has been suggested as a potential therapeutic agent for multiple sclerosis (Eur. J. Immunol. [1971] 1:242; and J. Neurol. Sci. [1977] 31:433; K.P. Johnson, *1 Neurology* 65-70 (1995); N. Engl. J. Med. [1987] 317: 408) and other immune system conditions, such as immune diseases and delayed-type  
10 hyper-sensitivity conditions (WO 00/05250). This drug is a synthetic polypeptide functionally crossreactive with myelin basic protein (MBP). MBP is a natural component of the myelin sheath.

15 Copolymer 1 has been shown to suppress experimental allergic encephalomyelitis (EAE) induced by various encephalitogens, including mouse spinal cord homogenate (MSCH). MSCH encompasses all myelin antigens, such as MBP (Sela M. et al., 88 *Bull. Inst. Pasteur* 303-314 (1990), proteolipid protein (PLP) (Teitelbaum,  
20 D. et al., *J. Neuroimmunol.* (1996) 64: 209-217) and myelin oligodendrocyte glycoprotein (MOG) (Ben-Nun A et al., 243 *J. Neurol.* (Suppl 1) S14-S22 (1996)) in a variety of species. EAE is an accepted model for multiple sclerosis.

25 It has also been demonstrated that Copolymer 1 is active when injected subcutaneously, intra-peritoneally, intravenously or intramuscularly (D. Teitelbaum et al., *Eur. J. Immunol.* (1971) 1:242-248; D. Teitelbaum et al., *Eur. J. Immunol.* (1973) 3:273-279). For instance, in phase III clinical trials, daily  
30 subcutaneous injections of Copolymer 1 were found to slow progression of disability and reduce the relapse rate in exacerbating-remitting multiple sclerosis (K.P. Johnson, *1 Neurology* 65-70 (1995); N. Engl. J. Med. [1987] 317: 408).

35 Currently, all approved treatments of multiple sclerosis involve

subcutaneous injection of the active substance. Frequently observed injection-site reactions include irritation, hypersensitivity, inflammation and pain and even necrosis (in the case of at least one interferon  $\beta$  1-b treatment) and a low level of patient compliance. Therefore, an alternative method of administration is desirable. Thus, in order to effectively treat chronic diseases such as autoimmune diseases, oral, nasal or pulmonary formulations and methods for producing such formulations are necessary.

One way to overcome the difficulties in subcutaneous injection of drugs is to create a form that can be taken orally. EP Patent 359,783 discloses the treatment of autoimmune disease by oral administration of autoantigens. In addition, it describes the oral administration of MBP for the treatment of multiple sclerosis. Oral administration of an autoantigen has been termed "oral tolerance".

PCT International Application Nos. WO 91/12816, WO 91/08760, and WO 92/06704 all depict the treatment of autoimmune diseases other than multiple sclerosis using the "oral tolerance" method with a variety of autoantigens. However, none of these references disclose the treatment of multiple sclerosis or other autoimmune diseases by the oral administration of a non-autoantigen such as Copolymer 1.

The invention also encompasses another avenue of administration that avoids the problems inherent in subcutaneous injection. This avenue is to produce a form of the drug that can be administered nasally.

#### **Summary of the Invention**

The disclosed invention provides pharmaceutical compositions useful for treating autoimmune diseases in a mammal comprising

as an active ingredient a therapeutically effective amount of Copolymer 1, and microcrystalline cellulose. Processes for the manufacture of such compositions are also disclosed.

5    **Description of the Drawings**

10    **Figure 1** shows the results of trials ascertaining prevention and treatment of EAE in Rhesus monkeys fed with Copolymer 1 (glatiramer acetate - "GA") enteric coated capsules.

15    **Figure 2** shows prevention of EAE in Rhesus monkeys fed with Copolymer 1 enteric coated capsules.

20    **Figure 3** shows the drug release profile of Copolymer 1 enteric-coated tablets.

25    **Figure 4** shows the effect of daily oral Gavage treatment with Copolymer 1 solution on rat EAE.

30    **Figure 5** shows the results of treatment of chronic-relapsing (CR)-EAE in Biozzi mice with oral Copolymer 1 solution.

35    **Figure 6** shows the results of treatment of EAE treatment in Cynomolgus monkeys by oral administration of Copolymer 1 in enteric-coated tablets.

40    **Detailed Description of the Invention**

45    This invention provides a pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of Copolymer 1, and microcrystalline cellulose.

50    The amount of microcrystalline cellulose is at least 50 % by

weight, preferably from about 60% to about 90% by weight, more preferably at least 70 % by weight, most preferably from about 70% to about 80% by weight.

- 5 The microcrystalline cellulose may have a moisture content of up to 5.0% or a moisture content of up to 1.5%.

10 The pharmaceutical composition may further comprise a disintegrant. The disintegrant may be selected from the group consisting of kaolin, starch, powdered sugar, sodium starch glycolate, crosscarmellose sodium, carboxymethyl cellulose, microcrystalline cellulose and sodium alginate. Preferably, the disintegrant is a pregelatinized starch. The starch may have a moisture content of up to 14%, preferably a moisture content of up to 12%, more preferably a moisture content of up to 7%, most preferably a moisture content of up to 5%.

20 The pharmaceutical composition may further comprise a lubricant. The lubricant may be selected from the group consisting of talc, sodium stearyl fumarate, magnesium stearate, calcium stearate, hydrogenated castor oil, hydrogenated soybean oil, and polyethylene glycol. Preferably, the lubricant is magnesium stearate.

- 25 The pharmaceutical composition may further comprise a protease inhibitor.

30 The pharmaceutical composition may further comprise an enteric coating. The enteric coating may be methacrylic ester copolymer, cellulose acetate phthalate (CAP), hydroxypropyl methyl cellulose phthalate (HPMCP), carboxymethyl ethyl cellulose (CMEC), amino-alkylmethacrylate copolymer. Preferably, the enteric coating is methacrylic acid copolymer.

- 35 The pharmaceutical composition may further comprise a film



coating under the enteric coating. The film coating may be selected from the group consisting of hydroxy propyl methyl cellulose (HPMC) and poly vinyl alcohol (PVA).

- 5 The pharmaceutical composition may be in solid form. The solid form may be selected from the group consisting of a tablet, a hard gelatin capsule, a pellet and a particulate formulation.

When the pharmaceutical composition is in solid form, it may be  
10 a tablet and the effective amount of Copolymer 1 is from about 0.1 mg to about 300 mg, preferably from about 5 mg to about 100 mg. In another embodiment, the effective amount of Copolymer 1 is from about 5 mg to about 50 mg. In a preferred composition, the effective amount of Copolymer 1 is about 5 mg. In another  
15 preferred embodiment, the effective amount of Copolymer 1 is about 10 mg. In a further preferred composition, the effective amount of Copolymer 1 is about 50 mg. In one embodiment, the effective amount of Copolymer 1 (glatiramer acetate) is about 0.01 mg/kg to about 2 mg/kg. In a preferred composition, the  
20 effective amount of Copolymer 1 (glatiramer acetate) is about 0.05 mg/kg to about 1 mg/kg.

In a preferred embodiment, the pharmaceutical composition in solid form comprises as an active ingredient a therapeutically  
25 effective amount of Copolymer 1, 70%-80% by weight of microcrystalline cellulose, an enteric coating, and either 5 mg or 50 mg of Copolymer 1.

The pharmaceutical composition may further comprise a  
30 pharmaceutically acceptable carrier suitable for application to mucosal linings, so as to thereby form a composition suitable for application to the mucosal linings of a subject. Preferably, the carrier is chitosan.

35 The pharmaceutical composition may further comprise a

pharmaceutically effective amount of an anti-microbial preservative. The anti-microbial preservative may be selected from the group consisting of sodium benzoate, methyl paraben, benzalkonium chloride, and propyl paraben.

5

According to this invention, the pharmaceutical composition may be in either aqueous form, or in dry powder form.

The mucosal linings to which the pharmaceutical composition may be administered may be bronchi-associated lymphoid tissue.

10

The pharmaceutical composition may be formulated for either oral administration, buccal administration, nasal administration, or pulmonary administration.

15

Also disclosed is a process for manufacturing the pharmaceutical composition, wherein the process comprises a) milling the Copolymer 1, and b) dry mixing and/or granulating the milled Copolymer 1 with at least 50% by weight of microcrystalline cellulose.

20

The process may further comprise applying a film coating or applying an enteric coating. The enteric coating may be applied using a rotating pan system.

25

Also disclosed is a method for treating an autoimmune disease in a mammal which comprises administering to the mammal the pharmaceutical composition according to this invention. The autoimmune disease is selected from the group consisting of an arthritic condition, autoimmune hemolytic anemia, autoimmune oophoritis, autoimmune uveoretinitis, Crohn's disease, chronic immune thrombocytopenic purpura, colitis, contact sensitivity disease, Graves disease, Guillain-Barre's syndrome, Hashimoto's disease, idiopathic myxedema, myasthenia gravis, psoriasis, pemphigus vulgaris, rheumatoid arthritis, GVHD or HVGD.

30

35

Preferably, the autoimmune disease is multiple sclerosis.

Thus, this invention provides a method for treating autoimmune diseases by oral administration of Copolymer 1. When Copolymer  
5 1 is introduced orally, it may be mixed with other food forms and consumed in solid, semi-solid, suspension or emulsion form; and it may be mixed with pharmaceutically acceptable carriers, including water, suspending agents, emulsifying agents, adjuvants, flavor enhancers and the like. In one embodiment,  
10 the oral composition is enterically-coated. Use of enteric coatings are well known in the art. Commonly known enteric coatings include Eudragit S and Eudragit L (K. Lehman, Acrylic Coatings in Controlled Release Tablet Manufacture, Manufacturing Chemist and Aerosol News, p. 39 (June 1973); K. Lehman,  
15 Programmed Drug Release from Oral Program Forms, Pharma. Int., vol. ISS 3 1971, p. 34-41; Handbook of Pharmaceutical Excipients, 2<sup>nd</sup> ed.).

An additional object of the present invention is to provide  
20 forms of Copolymer 1 that can be administered nasally to treat autoimmune conditions. For instance, Copolymer 1 may be administered as dry powder or metered dose of solution by inhalation, or nose-drops and nasal sprays, using appropriate formulations and metered dosing units. These formulations are  
25 intended to deliver Copolymer 1 to either (i) mucosal linings of the lungs and associated airways or (ii) mucosal linings of the nasal cavities.

As contemplated, Copolymer 1 is brought into contact with those  
30 lymphoid tissues in the mucosal linings which are believed to be a primary source of immune system sensitization. These mucosal linings may be found (though not necessarily exclusively) in the sinuses, trachea, bronchial passages (where they are known as the BALT or bronchi-associated lymphoid tissues) and  
35 gastrointestinal linings (known as GALT or gut-associated

lymphoid tissues). Thus, the administration of Copolymer 1 is understood to include methods wherein Copolymer 1 is introduced into the body by way of ingestion or inhalation. For example, Copolymer 1 may be administered by way of the mouth through  
5 feeding, through a stomach tube, by inhalation into the bronchial passages or by nasal inhalation.

The composition contemplated by the subject invention may be administered either as a simple oral solution, as an emulsion or  
10 suspension formulation, as a solid oral dosage form (capsule or tablet), or even as a soft gelatin capsule. The present invention contemplates immediate release dosage forms and modified release dosage forms (including particulates, coated granules and pellets, emulsions, microemulsions and  
15 encapsulation in microspheres and nanospheres).

Coated formulations may include enteric and non-enteric formulations. Enteric-coated dosage forms include the enteric-coated tablet, soft and hard gelatin capsule, pellet, particle  
20 and microparticle formulations. For instance, one may employ Eudragit (methacrylic acid copolymer) or Opadry (hydroxy propyl methyl cullulose ("HPMC") or poly vinyl alcohol ("PVA")) coatings, designed to target release by pH control in the stomach or in the gut, in the duodenum, jejunum, ileum or colon.  
25 Control of release may also be achieved through matrix erosion or time release formulations. Inactive ingredients can include lactose, microcrystalline cellulose, mannitol, PVP, starch, sodium starch glycolate, stearic acid, talc, hydrogenated triglycerides, polylactic acid and polyglycolic acid copolymers,  
30 or other ingredients intended specifically to enhance gut absorption.

Solid oral dosage form manufacturing processes can include direct compression and tableting, dry granulation, wet  
35 granulation, particulate and pellet manufacture by extrusion,

spheronisation and melt granulation. The bulk drug substance may be mixed or milled prior to blending with other excipients, or co-dissolved and sprayed in a solution in a wet granulation process. Spray drying may also be an appropriate method to achieve therapeutically important particulate formulations with or without an inactive ingredient (such as lactose). The amount of active ingredient within the composition can be in the range of 0.01 mg to 1000 mg, while the range 0.1 mg to 300 mg is likely to be optimal.

Autoimmune diseases contemplated by the present invention include either cell-mediated disease (e.g., T cell) or antibody-mediated (e.g., B cell) disorders. Such disorders can be *inter alia*, arthritic conditions, demyelinating diseases and inflammatory diseases. For example, autoimmune diseases which can be treated by the present compositions include multiple sclerosis, arthritic conditions, autoimmune hemolytic anemia, autoimmune oophoritis, autoimmune uveoretinitis, Crohn's disease, chronic immune thrombocytopenic purpura, colitis, contact sensitivity disease, Graves disease, Guillain-Barre's syndrome, Hashimoto's disease, idiopathic myxedema,, myasthenia gravis, psoriasis, pemphigus vulgaris, rheumatoid arthritis, and GVHD or HVGD. The present compositions can be used to treat one or more of these diseases.

The phrase, "arthritic condition", as used herein is a condition wherein at least one symptom of rheumatoid arthritis is observed in at least one joint of a mammal, for example in a shoulder, knee, hip, backbone or digit. Examples of arthritic conditions include "polyarthrititis", which is an arthritic condition that affects more than a single joint; "juvenile arthritis", an arthritic condition of humans under the age of 21; and Felty's syndrome, which can include the symptoms of neutropenia, splenomegaly, weight loss, anemia, lymphadenopathy, and pigment spots on the skin.

It is to be understood and expected that variations in the principles of invention herein disclosed may be made by one skilled in the art and it is intended that such modifications are to be included within the scope of the present invention.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2218  
2219  
2220  
2221  
2222  
2223  
2224  
2225  
2226  
2227  
2228  
2229  
2230  
2231

## Experimental Details

### EXAMPLE 1: PRODUCTION OF ENTERIC-COATED CAPSULES AND TABLETS

#### 5 Experiment 1A

Initial pre-clinical and clinical studies were performed using enteric-coated hard gelatin capsule formulations. All formulations were tested to meet (i) assay and impurities  
10 specifications, (ii) quality specifications for Copolymer 1, (iii) USP requirements for uniformity of dosage units by content uniformity and (iv) USP requirements for drug release for delayed release (enteric-coated) articles. Together, these tests were intended to ensure that each lot meets the necessary  
15 requirements for identity, strength, quality and purity.

Experimental lots of enteric-coated hard gelatin capsules were prepared for initial evaluation in monkeys suffering from EAE, manufactured using co-lyophilized Copolymer 1 and mannitol,  
20 sieved and hand-filled into hard gelatin capsules. The capsules were film-coated with Opadry (white) (commercial grades of hydroxy propyl methyl cellulose (HPMC) coating formulations marketed by Colorcon® (UK)) and then enteric-coated using methacrylic acid copolymer NF (Eudragit L-30 D-55, a commercial  
25 grade of methacrylic acid copolymer, available as a stabilized 30% aqueous dispersion, manufactured by Rohm® (Germany)) using a Würster fluid bed dryer (Accelacota 10).

The methacrylic acid copolymer used was Eudragit L 30 D-55,  
30 which is an aqueous dispersion of a methacrylic acid and acrylic acid ethyl ester. The ratio of free carbonyl groups to ester groups is 1:1. The films dissolve above pH 5.5 forming salts with alkali, thus affording coatings which are insoluble in gastric media, but soluble in the small intestine.

35

**Table 1** lists the inactive ingredients employed in the hard gelatin capsules and the purpose of each component. Capsules containing 1 mg and 20 mg of active ingredient were developed.

5      TABLE 1: Excipients in Hard Gelatin Capsule Formulations

Inactive Ingredient	Pharmaceutical Function
<i>Powder-Fill</i>	
Lactose Monohydrate NF	Filler
Silicon Dioxide NF	Glidant
Pregelatinized Starch NF	Disintegrant
Magnesium Stearate NF	Lubricant
<i>Film-Coating Suspension</i>	
Opadry YS-1-7006 (clear)	Film coating
Purified Water USP	Coating suspension solvent*
<i>Enteric-Coating Suspension</i>	
Methacrylic Acid Copolymer NF (Eudragit L-30 D-55)	Enteric-coating
Talc USP	Glidant
Triethyl Citrate NF	Plasticizer
Purified Water USP	Coating suspension solvent*

\*Coating solvent evaporated to dryness



i) Composition

TABLE 2

Components Strength	Composition (mg/capsule)	
	1 mg	20 mg
<i>Powder Fill</i>		
Copolymer 1	1.0	20.0
Mannitol USP	48.8	17.5
<i>Seal coat</i>		
Opadry (S-OY-7399) white	32.7	32.7
Purified Water USP	*	*
<i>Enteric Coat</i>		
Merthacrylic acid copolymer NF (Eudragit L30 D55)	20.3	20.3
Talc USP	10.3	10.3
Triethyl citrate NF	2.1	2.1
Purified Water USP	*	*

\* Processing solvent evaporated to dryness.

(ii) Manufacturing Process

1. Compounding of solution of 1.2 L of Copolymer 1 and mannitol in water
2. Lyophilization in bulk in Edward's lyoflex 0.5 pilot lyophilizer
3. Sieving - mesh #20/mesh#50.
4. Capsule filing - semi-manual Feton capsule filing machine.
5. Film coating Opadry (S-OY-7399 white) in Würster fluid bed dryer.
6. Enteric coating (Eudragit L30 D55 spraying suspension) in Würster fluid bed dryer.

Rhesus monkeys were fed with the enteric coated capsules. 5

feedings before disease induction and 5 feedings after disease induction, on alternate days. Experimental allergic Encephalomyelitis (EAE) was induced by injecting 8 mg myelin basic protein (MBP) in complete Freund's adjuvant (CFA) intradermally into the leg. EAE symptoms were evaluated on the following scale:

Evaluation of EAE clinical signs:

Score	Clinical State
0	Normal neurological exam and appearance
1	Weight loss, anorexia, yawning, slow responses to stimuli, irritability or lethargy
2	Mild neurological signs, indifference, drooling, clumsiness using limbs, ataxia, tremor, altered cry and disordered gaze
3	Moderate neurological signs, blindness (pupils do not react to light), akinesia, leg weakness or paralysis
4	Severe neurological signs, semicoma, coma, quadriplegia. When the animal reached a score of 4 it was sacrificed for humane reasons
5	Death

As can be seen in Fig. 1, control animals developed EAE on day 25 post disease induction and died within 4 days from the disease.

Animals that were fed with 20 mg Copolymer 1 in enteric coated capsules did not develop any signs of disease till day 60, when it was sacrificed for histology. One animal per group was used.

The animal that was treated with 1 mg Copolymer 1 in enteric coated capsules developed some signs of disease (score 2<sup>+</sup>), but upon treatment with 20 mg capsules healed completely.

In a second study (Fig. 2), all monkeys treated with Copolymer 1 enteric coated capsules (1, 10, and 20 mg) were fully

protected from EAE while monkeys treated with Copolymer 1 in capsules which were not gastro-protective (opened in the stomach) or control capsule died from the disease, indicating the importance of the enteric coating in these dose levels (1 to 20 mg.).

#### Experiment 1B

The procedure of Experiment 1A was adapted to give a stable product under refrigerated conditions that (i) can be manufactured using standard industrial pharmaceutical processes and (ii) meets pre-defined quality specifications appropriate for initial clinical evaluation. Here, the previous experiment's process of manufacturing the powder-fill was replaced by a dry granulation process.

(i) Composition

TABLE 3

Components	composition mg/capsule		
	Placebo	20 mg	100 mg
<i>Powder Fill</i>			
Copolymer 1	0.0	20.0	100.0
Lactose monohydrate NF	322.7	36.6	183.2
Pregelatinized starch NF	37.3	6.7	33.3
Silicon Dioxide NF	9.3	1.7	8.3
Magnesium Stearate NF	3.7	0.7	3.3
<i>Seal Coat</i>			
Opadry (YS-1-7006 clear)	29.0	29.0	29.0
Purified Water USP	*	*	*
<i>Enteric Coat</i>			
Methacrylic acid copolymer NF (Eudragit L30 D55)	50.6	50.6	50.6
Talc USP	25.4	25.4	25.4
Triethyl citrate NF	8.0	8.0	8.0
Purified Water USP	*	*	*

\* Processing solvent evaporated to dryness.

(ii) Manufacturing process (6kg)

1. Milling of Copolymer 1 - (fitzmill milling machine)
2. Blending with excipients - Y-cone 15 blender
3. Compression of slugs (20mm, 1g) - Killian tableting machine
4. Granulation of slugs - Frevitt granulator, 0.8 mm net
5. Blending with excipients - Y-cone 15 blender
6. Capsule filling - Bosch 400 encapsulator.
7. Coating (Accelacota-10 rotating pan machine).

The clinical formulation was administered to patients suffering from multiple sclerosis (MS) in the framework of the Phase I study. It was demonstrated that Copolymer 1 (20, 100 and 300 mg.) in enteric coated capsules was tolerated and safe in MS

patients.

In addition, oral administration of Copolymer 1 in enteric coated capsules modified the cytokine profile in multiple sclerosis patients (increase of IL-10 and decrease in IL-2) indicating a possible clinical effect of this formulation in MS patients.

#### Experiment 1C

10

Enteric-coated tablets (7.0 mm, round, 20 mg active ingredient) were chosen for further toxicological evaluation in monkeys. To create a stable product at controlled room temperature, Experiment 1B's procedure was modified. The lactose monohydrate filler used in the capsule formulations was replaced with microcrystalline cellulose NF (Avicel PH 102) due to the observation of long-term incompatibility with the active ingredient (a Maillard reaction occurred under accelerated storage conditions that resulted in yellowing of the granulate inside the capsule). Sodium starch glycolate NF was employed as the disintegrant; the slightly more rapid drug release brought about by sodium starch glycolate NF assisted in the toxicological evaluation in monkeys, where the gut is shorter than in humans.

25

A different opadry grade (Y-1-7000H) was used, even though this is also hydroxy propyl methyl cellulose ("HPMC")-based.

A corresponding placebo formulation was also developed.

30

The microcrystalline cellulose used was Avicel® PH 102, although Avicel® PH 101, and Avicel® PH 112, all manufactured by FMC Corporation, could be used. Microcrystalline cellulose fillers were employed in the experiments for tablet formulation. The three different kinds of microcrystalline cellulose binders mentioned differ in moisture content. Avicel® PH 101 and

Avicel® PH 102 are both high moisture content microcrystalline cellulose binders having less than or equal to 5% moisture content. Avicel® PH 112 is a low moisture content microcrystalline cellulose binder having less than or equal to 5 1.5% moisture content. The mean particle size of Avicel® ranges from 20 to 200 microns. The mean particle size of Avicel® PH 102 is 100 microns.

(i) Composition

TABLE 4

5	Ingredients	Amount (mg) /Tablet	
		0 mg	20 mg
	<i>Tablet Core</i>		
	Copolymer 1	0.0	20.0
	Microcrystalline cellulose NF	105.2	71.5
	Silicon dioxide NF	2.9	2.5
10	Sodium starch glycolate NF	5.8	5.0
	Magnesium stearate NF	1.1	1.0
	<i>Enteric Coat</i>		
15	Methacrylic acid copolymer NF (Eudragit L-30 D-55)	9.4	9.4
	Talc USP	4.7	4.7
	Triethyl citrate NF	0.9	0.9
	Purified water USP	*	*
	Total coating weight per tablet	15.0	15.0
20	Final coated tablet weight	130.0	115.0

\* Processing solvent evaporated to dryness.

(ii) Manufacturing process (6 kg)

1. Milling of Copolymer 1 - (fitzmill milling machine)
- 25 2. Blending with excipients - Y-cone 15 blender
3. Compression of slugs (20 mm, 1g) - Killian tableting machine
4. Granulation of slugs - Frevitt granulator, 0.8 mm net
5. Blending with excipients - Y-cone 15 blender
- 30 6. Tableting - Killian tableting machine.
7. Coating (Accelacota-10 rotating pan machine).

Experiment 1D

Experiment 1C's procedure was adapted to create similar  
5 formulations of enteric-coated tablets for clinical evaluation  
in humans suffering from multiple sclerosis. Pregelatinized  
starch was employed as the disintegrant. Tablet shape and size  
were selected as appropriate for enteric administration and  
found to be suitable for the intended pharmaceutical  
10 manufacturing processes, including coating. The 5 mg active  
ingredient tablets (and corresponding placebos) were  
manufactured in the same shape and size as in Experiment 1C.  
The size and shape of the 50 mg active ingredient tablets (and  
corresponding placebos) was changed into 14.7 mm x 8.1 mm oval-  
15 shaped tablets appropriate for enteric administration and the  
intended pharmaceutical manufacturing processes, including  
coating.

Scale-up and process qualification studies were completed for 52  
20 kg lots of tablet cores for both the 5 mg and 50 mg active  
ingredient. The tablet cores' composition is presented below.



(i) Composition of Tablet Cores

TABLE 5

	Ingredients	amounts of active ingredient (mg/tablet)			
		0 mg	0 mg	5 mg	50 mg
5	<i>Tablet Core</i>				
	Copolymer 1	0.0	0.0	5.0	50.0
	Microcrystalline cellulose NF (Avicel PH 102)	105.2	366.0	86.5	316.0
	Silicon dioxide NF	2.9	10.0	2.5	10.0
10	Pregelatinized starch NF	5.8	20.0	5.0	20.0
	Magnesium stearate NF	1.1	4.0	1.0	4.0
	Total	115.0	400.0	100.0	400.0
	<i>Enteric Coat</i>				
15	Methlacrylic acid copolymer NF (Eudragit L-30 D-55)	9.4	21.9	9.4	21.9
	Talc USP	4.7	11.0	4.7	11.0
	Triethyl citrate NF	0.9	2.1	0.9	2.1
	Purified water USP	*	*	*	*
	Total coating weight per tablet	15.0	35.0	15.0	35.0
20	Final coated tablet weight	130.0	435.0	115.0	435.0

\* Processing solvent evaporated to dryness.

(ii) Manufacturing process (52 kg)

1. Milling of Copolymer 1 - (fitzmill milling machine)
- 25 2. Blending with excipients - Y-cone 120 blender
3. Compression of slugs (20 mm, 1g) - Killian tableting machine
4. Granulation of slugs - Frevitt granulator, 0.8 mm net
5. Blending with excipients - Y-cone 120 blender
- 30 6. Tableting - Killian tableting machine.
7. Coating sub-lots (Accelacota-10 rotating pan machine).

Accelerated stability testing (at 40°C/75% Relative Humidity) of lots with

- (i) different film-coating Opadry formulations; and
- (ii) different slug hardness values indicated that optimal formulations can be achieved by carefully controlling slug hardness and using L30 D55 Eudragit with or without Opadry film coat (or any other hydroxy propyl methyl cellulose (HPMC) formulation).

The dissolution profiles of the 5 mg and the 50 mg tablets were compared and found to be matching despite the four-fold difference in tablet weight. The dissolution profiles (in buffer at pH 6.8) are shown in Figure 3.

#### EXAMPLE 2: ORAL ADMINISTRATION OF COPOLYMER 1 SOLUTION

##### Example 2A:

##### Gavage Administration of Copolymer 1 in Solution to Rats

EAE was induced in Lewis rats by the injection of guinea pig spinal cord homogenate in CFA into the hind legs.

For EAE suppression, rats were fed with Copolymer 1 solution (0.1-10 mg/kg.) every day, starting from the day of EAE induction, up to day 24 (test termination).

Copolymer 1 inhibited EAE at all tested doses, with bimodal dose response pattern. The most effective doses were the lowest dose 0.1 mg/kg (see Fig. 4) and the highest dose of 10 mg/kg.

In all groups, Copolymer 1 delayed disease onset, reduced the % of sick rats, the severity of disease (as expressed by the mean score and the mean maximal score) and the disease duration.

Example 2B: Suppression of Chronic - Relapsing EAE in Biozzi Mice by Oral Administration of Copolymer 1 in Solution

5 The chronic - relapsing EAE model represents MS better due to its relapsing nature. It enables the demonstration of drug effect on a disease which is on-going, similar to the situation of treating the human disease, which is on-going.

10 Chronic - relapsing EAE was induced in female Biozzi mice by the injection of mouse spinal cord homogenate (MSCH) in CFA, following by re-injection of the encephalitogen one week later, in the same manner.

15 On day 16 when the mice were already sick (see Fig. 5), they were randomized into 4 groups and treated daily by either phosphate buffer saline (PBS) as control or with Copolymer 1 solution (0.5 mg/kg/day, 2.5 mg/kg/day and 12.5 mg/kg/day).

20 As can be seen in Fig. 5, treatment with Copolymer 1 reduced the EAE clinical symptoms of the second relapse in a dose-dependent manner. The most effective dose was 12.5 mg/kg. The suppressive effect was demonstrated in all parameters checked: the incidence of mice suffering from second relapse, the severity of symptoms and the duration of the relapse.

25

EXAMPLE 3: ORAL ADMINISTRATION OF COPOLYMER 1 TABLETS

Example 3A: Induction of Relapsing-Remitting EAE in Cynomolgus Monkeys

30

A relapsing-remitting form of EAE was induced by the injection of emulsified MBP in CFA containing 3mg/ml of Mycobacterium Tuberculosis (MT), intradermally into right & left footpads.

35 The daily dosages employed are presented in Table 6 below.

Observation was initiated on day 8. Local reaction was observed at the site of injection, an ulcer/or bleeding ulcer caused intermittent use of the foot and /or flexion of the toes. Neurological signs appeared on day 14 following induction, as shown in Table 6.

Table 6: Daily Clinical Score

Monkey I.D.	Dose	DAYS					
		14	15	16	17	18	19-32
Female Z-920	2.5 mg	3	3	5			
Female Z-929	5 mg	0	0	3	4*		
Female Z-485	10 mg	1	2	3	5		
Male Z-523	2.5 mg	0	2	3	3/4	4*	
Male Z-1669	5 mg	0	0	0	0	0	0
Male Z-701	10 mg	0	0	0	0	0	0

\* euthanized

Table 6 demonstrates that the appearance of EAE was acute, (grade 3). Two of the females died within 48 hours of onset of signs of EAE, whereas the third female was euthanized subsequent to the development of grade 4 signs (coma).

Only one male developed signs of EAE and was euthanized after it reached grade 4. The two males which did not develop signs of EAE were euthanized after 32 days.

Thus, the dose injected for the induction of EAE does not relate to the time interval between injection and appearance of signs

of EAE, or the severity of signs. The females were the first to develop the signs of EAE, and the first to die. Only a third of the males developed EAE.

5    Example 3B: Treatment of EAE in Cynomolgus Monkeys by Oral  
Administration of Copolymer 1 in Enteric-Coated Tablets

---

Twelve Cynomolgus monkeys weighing 3 to 4 kg at the age of approximately four years were randomly divided into four  
10 treatment groups. For 10 days on every alternate day (total of 5 treatments), each monkey was introduced with the tablets using tip coated forceps beyond the radix of the tongue, after which swallowing was assured. The groups were treated as follows:

- Group #1 (placebo control): four placebo tablets  
15 Group #2 (5 mg Copolymer 1 per treatment): one tablet of 5 mg Copolymer 1 and 3 placebo tablets  
Group #3 (10 mg Copolymer 1 per treatment): two tablets of 5 mg Copolymer 1 and 2 placebo tablets  
Group #4 (20 mg Copolymer 1 per treatment): four tablets of  
20 5 mg Copolymer 1.

Subsequently, following the procedure of Example 3A, EAE was induced in all monkeys by single injection with 2.5 mg of MBP per monkey. Simultaneously, each group began daily treatment  
25 with the same dose of Copolymer 1 as they received prior to the induction of EAE for 30 days.

In the first study, Cop-1 treatment continued until day 52. In the second study, Cop-1 treatment continued until day 57. MBP  
30 was administered in a single administration. Cop-1 was administered continuously except for several weekends in the first study, and except for Saturdays in the second study.

The monkeys were examined every Sunday to Friday, and also not  
35 monitored on Saturdays, starting from day 8 after disease induction until day 52. At the end of this period, the monkeys were sacrificed and the tissue was harvested.

Local reaction was observed at the site of injection, such as an ulcer and/or bleeding ulcer, which caused intermittent use of the foot and/or flexion of the toes. EAE-related neurological  
5 signs appeared between day 12 and 20 following induction, as specified in Table 7 below.

TABLE 7 Daily Clinical Score.

DOSE	0mg	0mg	0mg	5mg	5mg	5mg	10mg	10mg	10mg	20mg	20mg	20mg
MONKEY ID	607	623	427	540	495	662	1652	1654	493	453	484	482
5	12	0	0	0	0	0	0	0	0	0	0	2
	13	0	0	0	0	0	0	0	0	0	0	3
	14	0	0	0	0	0	0	0	0	0	0	**4
	15	0	0	0	0	0	1	0	0	0	2	4
	16	0	0	0/1	0	0	2	0	0	0/1	3	4
10	17	1	2	0/1	0	0	2	0	0	0/1	***5	4
	18	0	2	0/1	0	0	3	0	0	0	5	4
	19	0	2	0/1	0	0/1	3	2	0	0	5	4
	20	2	2	1	0/1	0/1	3	2	0/1	0	5	4
	21	2	2	1	0/1	1	3	2	0/1	0	5	4
15	22	2	2	1	0/1	0	3	2	0	0/1	5	4
	23	2	2	1	0/1	0/1	3	2	0/1	0	5	4
	24	1	0	0	0	0	2	0	0	0	5	4
	25	1	0	0	0	0	2	0	0	0	5	4
	26	0	0	0	0	0	2	0	0	0	5	4
20	27	0	0	0	0	0	2	2	0	0	5	4
	28	0	0	0	0	0	2	2	0	0	5	4
	29	0	0	0	0	0	2	2	0	0	5	4
	30	0	0	0/1	0	2	**4	0/1	0	0/1	5	4
	31											
25	32	2	0	0/1	0/1	2	4	0/1	0	0	5	4
	33	3	0	0/1	0/1	2	4	0/1	0	0	5	4
	34											
	35	3	0	1	0/1	2	4	2	0	0	5	4
	36	3	0	1	1	2	4	2	0	0	5	4
30	37											
	38	**4	0	1	1	1	4	2	0	0	5	4
	39	4	0	1	1	2	4	2	0	0	5	4
	40											
	41											
35	42	4	2	2	0	0	4	2	0	0	5	4
	43											
	44											
	45	4	2	3	0	0	4	2/3	0	0	5	4
	46	4	2	3	0/1	0	4	2	0	0	5	4
40	47	4	2	3	1	0	4	2	0	0	5	4
	48	4	2	2	1	0/1	4	2	0	0	5	4
	49	4	2	2	1	0	4	2	0	0	5	4
	50											
	51	4	2	2	1	0	4	2	0	0	5	4
45	52	4	2	2	1	0	4	2	0	0	5	4

\* The monkey was sacrificed for reasons not related to neurological scoring.

35 \*\* The monkey was sacrificed when it reached grade 4.

\*\*\* The monkey was found dead in the cage.

All three females in the placebo group showed signs of illness on days 17-23 followed by a remission period of a week. Female No. 607 had a second acute relapse on day 32 and was sacrificed on day 38 when score 4 was reached. Females No. 623 and 427 showed severe signs of illness in the last 10 days of follow up (scores 2 and 3).

In the 5 mg Copolymer 1 treatment group, Female No. 662 showed signs of illness on day 15 and by day 18, after losing her pupillary reflex, received score 3. On day 30, the animal was sacrificed after it reached score 4. The two other females, No. 540 and 495, had a similar sequence of symptoms, with mild signs on day 18/19 to day 23 (score 1) and a relapse between day 30/32 and day 39 (score 1-2). Female No. 540 had a third relapse between day 46 to day 52 (score 1).

In the group that was treated with 10 mg Copolymer 1, Female No. 1652 showed neurological symptoms from day 19 (score 2), with a short remission period between days 24-26 and 30-33(score 0/1) and survived to the end of the follow up period. Females No. 493 and 1654 showed irregular, very mild symptoms during the entire follow up period (score fluctuated between 0 and 0/1).

In the 20 mg Copolymer 1 treatment group, Females No. 482 and 484 showed a very acute onset of signs. Female No. 482 reached score 2 on day 12, 3 on day 13 and was euthanized on day 14 (score 4).

Female No. 484 registered score 2 on day 15, reached score 3 the following day and was found dead on day 17 (score 5). Female No. 453 had mild neurological symptoms, but because of suppurative infected inguinal lymph nodes and infected bleeding wounds of the foot pad, which caused the animal severe deterioration, the animal was sacrificed on day 26.



Seven females survived to the end of the follow up period and were sacrificed on day 53. Inguinal lymph nodes and sections of the intestine were harvested for immunochemical staining.

5 The results of this example are summarized in Table 8 below.

TABLE 8: Evaluation of Clinical Manifestations

10	Treatment Group	Incidence	Mean Score	Mean Maximal Score	No. Relapses*	Mean Disease Onset Day
	Control	3/3	1.27	3.00	3 (6)	16.66
	5 mg	3/3	1.30	2.33	2 (5)	18.33
	10 mg	1/3	0.49	1.33	1 (3)	23
	20 mg	3/3	3.04	3.67	0 (3)	14.33

15 In summary, the course of EAE was phasic, with recurrence of symptoms and remission periods. While the placebo group showed the chronic phasic pattern of the disease, leading to deterioration with time, the 20 mg Copolymer 1 treatment group had an acute onset of symptoms with a fulminate course of the  
20 disease and death. The group treated with 5 mg Copolymer 1 exhibited a pattern of disease similar to the placebo group with no obvious improvement. In the 10 mg Copolymer 1 group, two females showed irregular, very mild symptoms, while only one female showed more than very mild symptoms (score 2 with periods  
25 of remission to score 0/1). All three survived through the whole study. The difference among the placebo, 10 mg Copolymer 1 treatment group and 20 mg treatment Copolymer 1 group is significant ( $p < 0.0001$ ). However, the difference between the placebo group and the 5 mg group is not significant (n.s.) ( $p =$   
30 n.s.).

These results suggest that the most effective dosage is 10 mg Copolymer 1.

Example 3C: Treatment of EAE in Cynomolgus Monkeys by Oral  
Administration of Copolymer 1 in Enteric-Coated Tablets

5 The procedure of Example 3B was followed with the following  
exceptions - there was no 5 mg Copolymer 1 treatment group and  
the monkeys were observed until day 57 after disease induction.

10 As in Example 3B, observation began on day 8 and continued until  
the conclusion of the experiment, which, in this case, was day  
57. Local reaction was observed at the site of injection, such  
as an ulcer and/or bleeding ulcer, which caused intermittent use  
of the foot and/or flexion of the toes. EAE-related  
15 neurological signs appeared between day 14 and 54 as specified  
in Table 9. Animals were sacrificed when they reached score 4.

TABLE 9: Daily Clinical Score.

DOSE MONKEY ID.	0mg 171	0mg 203	0mg 895	10mg 268	10mg 318	10mg 307	20mg 285	20mg 793	20mg 494
DAYS	13	0	0	0	0	0	0	0	0
	14	2	0	3	0	1	0	0	0
	15	2	0	5	0	2	0	0	0
	16	2	0	5	0	2	0	2	0
	17								
	18	3	0	5	0	3	0	4	0
	19	3	0	5	0	3	0	4	0
	20	3	0	5	0	3	0	4	0
	21	2	0	5	0	3	0	4	0
	22	2	0	5	0	3	0	4	0
	23	2	1	5	0	3	0	4	0
	24								
	25	2	1	5	0	3	0	4	0
	26	2	1	5	0	3	0	4	0
	27	3	1	5	0	3	0	4	0
	28	3	1	5	0	3	0	4	0
	29	3	1	5	0	3	0	4	0
	30	3	1	5	0	3	0	4	0
	31								
	32	4	1	5	0	3	0	4	0
	33	4	1	5	0	2	0	4	0
	34	4	1	5	0	2	0	4	0
	35	4	1	5	0	2	0	4	0
	36	4	1	5	0	2	0	4	0
	37	4	1	5	1	2	0	4	0
	38								
	39	4	1	5	1	2	1	4	0
	40	4	1	5	1	2	2	4	0
	41	4	1	5	1	2	2	4	0
	42	4	1	5	1	2	2	4	0
	43	4	1	5	1	2	2	4	0
	44	4	1	5	1	2	2	4	0
	45	4							
	46	4	1	5	1	2	2	4	0
	47	4	0	5	1	2	2	4	0
	48	4	0	5	1	2	3	4	0
	49	4	0	5	1	2	3	4	0
	50	4	0	5	1	2	3	4	0
	51	4	0	5	1	2	3	4	0
	52								
	53	4	0	5	1	2	3	4	0
	54	4	0	5	1	2	3	4	1
	55	4	0	5	1	2	3	4	1
	56	4	0	5	1	2	3	4	1
	57	4	0	5	1	2	3	4	1

2025 RELEASE

In the group that received the placebo, two females showed signs of illness on day 14 (scores 2 and 3). Female No. 895 was found dead on day 15 (score 5) and Female No. 171 was sacrificed on day 32 when score 4 was reached. Female No. 203 showed only mild signs of illness (score 1) on days 23-46.

In the 10 mg Copolymer 1 treatment group, Female No. 268 showed mild signs of illness on day 37, which continued until the end of the follow up period. Female No. 307 had a similar onset of symptoms, with mild signs on day 39 (score 1) but reached score 2 on days 40-46, and score 3 from day 46 until the end of the follow up period. Female No. 318 showed signs of illness (score 1) on day 14, reached score 2 on days 15-16, and score 3 on days 18-32, with an improvement starting on day 33 (score 2) until the end of the follow up period. Overall, she exhibited very mild symptoms during the entire follow up period.

In the group that was treated with 20 mg Copolymer 1, Female No. 285 showed a very acute onset of signs. On day 16, she reached score 2, and was euthanized two days later on day 18 (score 4). Female No. 793 had mild neurological symptoms (score 1) from day 54 until the end of follow up period. Female No. 494 showed mild signs from day 20 to 36, and reached score 2 from day 37 to 46, with an improvement (score 1) until the end of the follow up period.

A summary of the results is presented in Table 10 below.

TABLE 10: Evaluation of Clinical Manifestations

Treatment Group	Incidence	Mean Score	Mean Maximal Score	Mean Disease Onset Day
Control	3/3	2.9 ± 0.6	3.33	17
10 mg	3/3	1.3 ± 0.56	2.33	30
20 mg	3/3	1.6 ± 0.53	2.33	30

A graphic summary appears in Figure 6. Six females survived to the end of the follow up period and were sacrificed on day 57.

The phasic course of the disease was not clear as in Example 3B, with recurrence of symptoms and remission periods. Most of the animals developed acute or chronic disease. Acute onset of EAE appeared in the placebo group in two animals and in the 20 mg Copolymer 1 treatment group in one animal. In the group that was treated with 10 mg Copolymer 1, the pattern of disease was not as severe as in the other groups -- all three animals developed chronic disease and survived through the whole study. The difference between the placebo group and the 10 mg Copolymer 1 group, and between the placebo group and the 20 mg Copolymer 1 group was statistically significant ( $p < 0.0001$ ). The difference is also significant between the 10 mg Copolymer 1 group and the 20 mg Copolymer 1 group ( $p < 0.03$ ). From evaluation of the clinical manifestations summarized in Table 10, it is evident that Copolymer 1 treatment does not change the incidence of the disease, but mainly affects the timing of the initial manifestation of the disease and the intensity of the symptoms. This data confirms the results of Example 3B, where the most effective dosage of Copolymer 1 was 10 mg.

Example 3D: Treatment of Relapsing - Remitting (RR) MS Patients  
With Copolymer 1 Enteric-Coated Tablets.

---

1,650 RR MS patients are recruited and randomized 1:1:1 into treatment with 5 mg Copolymer 1, 50 mg Copolymer 1 or placebo, in a framework of a phase III clinical trial. Patients are followed every 2 months for a total duration of 56 weeks.

The primary end point of the study is the reduction of relapse rate by the treatment with Copolymer 1 enteric-coated tablets.

In the secondary outcome measures, the effect of Copolymer 1 on disease activity and burden of disease are monitored using magnetic resonance imaging (MRI).

- 5 In addition, the effect on brain atrophy, magnetization transfer (MT), spectroscopy (MRS) and disability are also being monitored, in order to demonstrate the effect of oral administration of Copolymer 1 in enteric-coated tablets on disease progression.

10

#### DISCUSSION

- When preparing oral formulations, characteristics such as desired site of action (e.g. gut), dosage amount, physical characteristics, and chemical characteristics, must be taken  
15 into consideration.

- Copolymer 1 is a non-crystalline, highly porous, lyophilized material. It is only slightly soluble, and has poor mixing and very poor flow properties. In addition, Copolymer 1 is a  
20 proteinaceous material which is easily degraded by proteolytic enzymes in the gastrointestinal track. This disclosure provides Copolymer 1 formulations for oral administration which have pharmaceutical properties suitable for oral administration.

- 25 While microcrystalline cellulose has been used as a component in oral formulations, the formulations disclosed herein contain in excess of 50% by weight of microcrystalline cellulose. Such a composition, together with the disclosed milling/dry granulation manufacturing process results in oral formulations with  
30 excellent flow and mixing characteristics, improved dissolution and improved stability than that which could have been expected based on the properties of Copolymer 1.

Indeed, based on the properties of Copolymer 1, it was unexpected that formulation with microcrystalline cellulose, particularly in excess of 50%, would have significantly improved pharmaceutical properties suitable for oral administration.

The advantageous properties of the disclosed formulation include that it allows for matching *in vitro* dissolution profiles of the 5 mg Copolymer 1 and the 50 mg Copolymer 1 tablets, despite a 4-fold difference in tablet weight as shown in Figure 3. Specifically, and unexpectedly, even though the 50 mg Copolymer 1 tablet is four times the weight of the 5 mg Copolymer 1 tablet, the tablets have similar dissolution profiles.